Patent US5336263A successfully refreshed from Google Patents.
US5336263A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of urological and gastric fluid reflux disorders by injection of mmicro particles
Assignee: Uroplasty LLC
•
Filing: 1993-04-22
•
Granted: 1994-08-09
•
Expires: 2013-04-22
Abstract
Abstract Novel principles for treating urological and gastric fluid reflux disorders are disclosed wherein textured micro particles having a combination of average unidimensional particle size range and average particle texture which cooperate substantially to prevent loss of the micro particles from any injection site.
Inventors
- 👤 Robert A. Ersek
- 👤 Arthur A. Beisang
- 👤 Arthur A. Beisang, III
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:07
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/0004; A61F2/0031; A61F2/0036; A61L; A61L27/00; A61L27/14; A61L27/16; A61L27/18; A61L27/50; A61F2/02; A61F2/30; A61F2002/30001; A61F2002/30108; A61F2002/30199; A61F2002/30303; A61F2230/00; A61F2230/0063; Y; Y10; Y10S; Y10S623/00; Y10S623/92
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
125 words
A method for long-term treatment of urological and gastric disorders comprising the step of injecting submucosally or peri-urethrally into tissue at at least one injection site a composition comprising an effective amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average particle size distribution and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 2
Independent Claim
125 words
A method for long-term treatment of urological and gastric disorders comprising the step of injecting submucosally or peri-urethrally into tissue at at least one injection site a composition comprising an effective amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average particle size distribution and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 3
Dependent Claim
29 words
A method as defined in claim 1 wherein the micro particles possess an average unidimensional particle size in the range of from about 100 microns to about 600 microns.
Claim 4
Dependent Claim
14 words
A method as defined in claim 1 wherein the micro particles comprise a polysiloxane.
Claim 5
Dependent Claim
14 words
A method as defined in claim 2 wherein the micro particles comprise a polysiloxane.
Claim 6
Dependent Claim
13 words
A method as defined in claim 2 wherein the micro particles are polydimethylsiloxane.
Claim 7
Independent Claim
163 words
A method for long-term treatment of incontinence comprising the steps of making a plurality of spaced injections into the submucosal layer of the urethra of a composition comprising an amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average unidimensional particle size distribution between 30 and 3000 microns, and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, characterized by indentations, cavities and pores forming openings upon the surface of the particles, with the dimensions of the indentations, cavities and pores being generally in a range between 10 angstroms and 500 microns, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 8
Independent Claim
163 words
A method for long-term treatment of incontinence comprising the steps of making a plurality of spaced injections into the submucosal layer of the urethra of a composition comprising an amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average unidimensional particle size distribution between 30 and 3000 microns, and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, characterized by indentations, cavities and pores forming openings upon the surface of the particles, with the dimensions of the indentations, cavities and pores being generally in a range between 10 angstroms and 500 microns, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 9
Dependent Claim
29 words
A method as defined in claim 6 wherein the micro particles possess an average unidimensional particle size in the range of from about 100 microns to about 600 microns.
Claim 10
Dependent Claim
15 words
A method is defined in claim 6 wherein the micro particles comprise a polysiloxane material.
Claim 11
Dependent Claim
14 words
A method as defined in claim 7 wherein the micro particles comprise a polysiloxane.
Claim 12
Independent Claim
170 words
A method for long-term treatment of gastric reflux comprising the steps of making a plurality of injections at spaced sites into the appropriate submucosal space selected from the esophageal-gastric junction and gastric-pyloric junction a composition comprising an amount of relatively soft, malleable, elastic, biologically compatible micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average unidimensional particle size distribution between 30 and 3000 microns, and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, characterized by indentations, cavities and pores forming openings upon the surface of the particles, with the dimensions of the indentations, cavities and pores being generally in a range between 10 angstroms and 500 microns, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 13
Independent Claim
170 words
A method for long-term treatment of gastric reflux comprising the steps of making a plurality of injections at spaced sites into the appropriate submucosal space selected from the esophageal-gastric junction and gastric-pyloric junction a composition comprising an amount of relatively soft, malleable, elastic, biologically compatible micro particles dispersed in a non-retentive compatible physiological vehicle comprising polyvinyl pyrrolidone, the micro particles of the composition further being of a designed average unidimensional particle size distribution between 30 and 3000 microns, and characterized by a rough surface having a plurality of surface irregularities generally randomly formed therein, characterized by indentations, cavities and pores forming openings upon the surface of the particles, with the dimensions of the indentations, cavities and pores being generally in a range between 10 angstroms and 500 microns, such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 14
Dependent Claim
29 words
A method as defined in claim 10 wherein the micro particles possess an average unidimensional particle size in the range of from about 100 microns to about 600 microns.
Claim 15
Dependent Claim
15 words
A method is defined in claim 10 wherein the micro particles comprise a polysiloxane material.
Claim 16
Dependent Claim
15 words
A method is defined in claim 11 wherein the micro particles comprise a polysiloxane material.
Claim 17
Independent Claim
129 words
A method for long-term treatment of urological and gastric disorders comprising the step of injecting submucosally or peri-urethrally into tissue at at least one injection site a composition comprising an effective amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles, characterized by a rough surface having a plurality of irregularities generally randomly formed therein, and dispersed in a non-retentive, non-retained compatible physiological vehicle, wherein the vehicle is eliminated from the injection site and the micro particles being an average particle size distribution and surface roughness such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 18
Independent Claim
129 words
A method for long-term treatment of urological and gastric disorders comprising the step of injecting submucosally or peri-urethrally into tissue at at least one injection site a composition comprising an effective amount of relatively soft, malleable, elastic, biologically compatible prosthetic micro particles, characterized by a rough surface having a plurality of irregularities generally randomly formed therein, and dispersed in a non-retentive, non-retained compatible physiological vehicle, wherein the vehicle is eliminated from the injection site and the micro particles being an average particle size distribution and surface roughness such that the effects of average particle size and average particle surface roughness cooperate in combination in an autogenous manner to essentially prevent loss of the micro particles from any injection site, the particles remaining to be incorporated as long-term tissue augmentation.
Claim 19
Dependent Claim
68 words
A method as defined in claim 14 wherein the surface irregularities of the micro particles describe indentations, cavities and pores forming a very irregular surface including openings within the particles, the micro particles having an average unidimensional particle size generally between 30 and 3000 microns with the dimensions of the indentations, cavities and pores within the particles being generally in a range between 10 angstroms and 500 microns.
Claim 20
Dependent Claim
11 words
The method of claim 15 wherein the vehicle comprises polyvinyl pyrrolidone.
Claim 21
Dependent Claim
22 words
A method as defined in claim 15 wherein the micro particles possess an average unidimensional particle size of 100 microns or more.
Claim 22
Dependent Claim
35 words
A method as defined in claim 17 wherein the composition is injected into a submucosal space selected from the bladder-urethral junction, the esophageal-gastric junction and the gastric-pyloric junction using a plurality of spaced injection sites.
Claim 23
Dependent Claim
25 words
A method as defined in claim 16 wherein the composition is injected under the intravesical portion of the ureter using a plurality of spaced injections.
Claim 24
Dependent Claim
25 words
A method as defined in claim 17 wherein the composition is injected under the intravesical portion of the ureter using a plurality of spaced injections.
References Cited (Backward Citations)
US3638649A
Cited
US3657744A
Cited
US4197846A
Cited
US4093576A
Cited
US4061731A
Cited
US4212857A
Cited
US4186189A
Cited
US4138382A
Cited
US4239492A
Cited
US4240794A
Cited
EP0022724A1
Cited
DE3038047A1
Cited
US4341691A
Cited
US4424208A
Cited
US4582640A
Cited
US4565580A
Cited
GB2139898A
Cited
US4469676A
Cited
US4592864A
Cited
US4631188A
Cited
US4652441A
Cited
US4837285A
Cited
WO1986003671A1
Cited
EP0206726A2
Cited
WO1987005521A1
Cited
EP0251695A2
Cited
US4803075A
Cited
US4773393A
Cited
US4828827A
Cited
WO1988006873A1
Cited
WO1988007355A1
Cited
US4894231A
Cited
US4882607A
Cited
US5011494A
Cited
GB2227176A
Cited
US5067965A
Cited
US5077940A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-08-08 | 1998-02-07 | 1998-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-08-08 | 2002-02-07 | 2002-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-08-08 | 2006-02-07 | 2006-08-09 | $7700.00 | Window Closed / Lapsed |